Canada is a country presenting interesting assets for European companies undergoing international expansion, as expressed by the SME members of the bioXclusters+ regions, Auvergne-Rhône-Alps (Lyonbiopole), Bavaria (BioM), Catalonia (Biocat) and Piedmont (bioPmed).
In order to build up collaboration opportunities, the bioXclusters+ alliance, the European Strategic Cluster Partnership on Personalised Healthcare – co-funded by the COSME Programme of the European Union -, has started discussions with some cluster organisations during BIO Intl. Convention in San Francisco in June 2016. Among them, TOHealth!, an industry-led public private partnership, working as the Toronto Cluster organisation, shares our strong interest to foster external relations and our a strong focus in Personalized Healthcare. Apart from this, a mutual collaboration MoU has been signed between TOHealth! (link) and bioXclusters plus in December 2016 for building bioXclusters+ gateways in Canada.
To that end, bioXclusters+ is organizing a session within BIO-Europe Spring 2017 to compare business environments for the development and internationalization of personalized and precision medicine between Canada and Europe. Cluster representatives will take part to share best practices and main actors of a succeded business expansion case story across the Atlantic Ocean: Catalan biotechnology firm Mosaic Biomedicals, a spin-off of the Vall d’Hebron Institute of Oncology, merged earlier this year with Canadian firm Northern Biologics to accelerate development of a new antibody that attacks a protein responsible for the spread of cancer (MSC-1) and to begin clinical trials at several leading hospitals in Europe and the United States in 2017. Mosaic Biomedicals is a company belonging to the Bioregion of Catalonia while Northern Biologics is one of the members of TOHealth! Initiative making this a perfect example to study the success factors which promote transatlantic cooperation betweet two clusters. In this session, Judit Anidó (Co-founder & CEO, Mosaic Biomedicals) and Stefan Larson (CEO – Northern Biologicals) will share their experience, offer key advice and learned lessons for stimulating synergies and innovation.
BIO-Europe Spring (BES) is one of the main partnering events in europe. Next edition, BES will take place in Barcelona from 20th to 22nd of March. This fair will be gathering more than 2,500 professionals and 1,300 companies from biotech, pharma and financing sectors.
We believe that this is an awesome opportunity for life sciences clusters from all over the world as well as SMEs involved in precision medicine products and services. We will be very happy to welcome them to our session, the open discussion and networking after the presentations.
Our session entitled Transatlantic cooperation in Precision Medicine: an example from Canada & Europe M&A’s will take place on the CCIB Convention Centre, Barcelona, Spain, Tuesday, March 21st, 2017, 12:00 – 13.30 a.m. You will be able to register here.